Upadacitinib Shows Promising Results Against Severe Alopecia Areata
**The oral medication upadacitinib, approved for various forms of arthritis, showed positive results in phase 3 trials against severe alopecia areata. However, its use for this condition is still under regulatory review and is not approved for that indication.
- Phase 3 Trials: Two studies evaluated upadacitinib in adolescents and adults with severe alopecia areata.**
- Hair Results: In the disclosed data, between 35.2% and 45.8% of patients treated in one of the trials achieved at least 90% scalp coverage, depending on the dose received.**
- No Approval for This Indication: Although upadacitinib is approved for various inflammatory diseases, its use against alopecia areata remains under regulatory review.**
A Treatment Created for Another Disease
An oral medication originally developed to control inflammation associated with various forms of arthritis is being evaluated as a potential alternative for people with severe alopecia areata. This is upadacitinib, a daily administration pill that was studied in international clinical trials with participants who had lost a very high proportion of hair from the scalp.
Alopecia areata is not simply a cosmetic issue. It is an autoimmune disease in which the immune system mistakenly attacks hair follicles, causing hair loss that can appear in patches or extend to compromise the entire scalp, eyebrows, and even body hair.
In the most severe cases, the loss can affect personal confidence, social life, and mental health of those affected. The possibility of regaining a significant amount of hair has made JAK pathway inhibitors an area of interest for dermatological research.
The researchers' hypothesis is based on a biological connection between both diseases. If upadacitinib can reduce an excessive immune reaction related to arthritis, it could also slow the attack on hair follicles and allow hair to regrow in some people with alopecia areata.
What the International Trials Showed
The phase 3 trials recruited adolescents and adults with severe alopecia areata to evaluate the safety and efficacy of the drug under controlled conditions. In the materials associated with the clinical program, participants presented extensive hair loss from the scalp, a characteristic that allows studying the treatment in more severe cases.
Participants were randomly assigned to different groups to receive a daily dose of 15 mg of upadacitinib, a daily dose of 30 mg, or a placebo. This design allowed comparing the response of those who received the medication with the evolution of those who did not receive the active ingredient.
The disclosed results show signs of hair recovery after 24 weeks. In one of the trials, 35.2% of patients who received 15 mg and 45.8% of those who received 30 mg achieved at least 90% scalp coverage, measured using the SALT scale, according to results communicated by AbbVie.
Another report on the phase 3 program informed proportions of 36% and 47.1%, respectively, for the same hair coverage threshold. The differences between the reported percentages may correspond to different trials or result cuts, so they should not be combined as if they were a single rate.
These data describe results from clinical trials and do not mean that all treated individuals will regain hair or that the benefit will last indefinitely. It is also important to distinguish between scalp coverage and complete hair recovery: achieving at least 90% coverage does not necessarily equate to regaining 100% of lost hair.
A Possible Answer for an Unpredictable Disease
Alopecia areata can behave unpredictably, with losses limited to small areas or with a progression that removes hair from the scalp and other parts of the body. This variability makes it relevant to study the treatment in people with extensive involvement and prolonged periods without new growth.
The recovery observed after 24 weeks represents a hopeful sign for patients facing severe loss, but the available results do not allow establishing by themselves how long the benefit lasts, what happens after stopping treatment, or which patient profiles respond better.
Moreover, upadacitinib is still not approved for treating alopecia areata. Its safety and efficacy for this indication are under regulatory review in the United States and Europe. Therefore, the results of the trials should be interpreted as clinical evidence under evaluation and not as authorization for a new treatment.
For now, the main value of these trials lies in showing that a medication designed for inflammatory diseases may have potential application in an autoimmune condition affecting hair follicles. The research opens a pathway of hope for those facing severe loss, although regulatory review, long-term follow-up, and a more comprehensive assessment of risks and benefits are still pending.
-- Price
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.
You may also like

Bitcoin on the Path to $11 Million... "The Power Law Will Break in 2036"

Yen Decline May Force Liquidations and Shake Global Markets

Solana ETF Surpasses $1 Billion, Highlighting Structural Differences with Ripple ETF

Crypto stock tokens barely move over weekend, revealing markets become illiquid when Wall Street goes offline

Miner Vps Reviews: A Check on the Telegram Bot for Renting Mining Servers

How Can Bitcoin Withstand Quantum Computers? A Comparison of Three Lattice-Based Signature Schemes

A Founder’s Reflection: Why Did Fomo Run Further Than Us from the Same Starting Point?

Automakers Become Indispensable in the Second Half of Embodied Intelligence

BCRA purchases exceeded $14 billion barrier in 2026

BlackRock's iShares Bitcoin Trust ETF regains weekly options expiries

Kraken Supports Solana Inflation Reform

JPMorgan’s IBIT Bitcoin ETF bet just missed its escape hatch to avoid 6% deduction

Solana Governance Proposal SGP-0002 Passed, Schwab to Support Trading

A Founder’s Reflection: Why Did Fomo Run Further Than Us from the Same Starting Point?

ERC-8196 Standard Finalized, Supporting AI Agent Wallet Strategy Execution

BIT Investment Opportunities Forum Held in Hong Kong, Discussing Next Phase of Market and Asset Allocation Opportunities
![[Kang Ryun-ho's Crypto Zoom-In] The Advancement of the Regulatory Framework for Virtual Asset Businesses and Practical Responses](/public-static/20_9098579959.png?format=avif)
[Kang Ryun-ho's Crypto Zoom-In] The Advancement of the Regulatory Framework for Virtual Asset Businesses and Practical Responses

Solana Faces a Choice: Preserve Staking or Rarify SOL?

Ethereum’s plan to triple network speed could silently break millions of existing smart contracts

Top 1% of Shiba Inu Requires 380 Million SHIB

Hash Global: After BTC, Who Will Take the Baton for the Next Bull Market?
How to Trade NVDA, AAPL, and Gold Without a Brokerage Account

With 34% of ETH Staked: How to Choose Staking in the Era of Native Compound Interest?

Private Air Defense from 20 Million UAH: Who Protects Ukrainian Businesses from Shelling and What Will Happen to the Market After the War

AMM Fee Optimization: DeFi Pools Lose Half of Their Value in Arbitrage

U.S. Bond Buybacks Release Liquidity! Arthur Hayes Bets on 'These 4 Cryptocurrencies' for the Bull Market

How one small BTC transfer exposed the fine print behind Trump’s ‘never sell’ strategic Bitcoin reserve

Who is vying for SRO status in the cryptocurrency exchange market? Why are they needed?

Wall Street Speculates: What’s Scott Bessent’s Next Move to 'Rescue' U.S. Debt?










